Comparison of multimodality treatment; 2 or 4 courses of Paclitaxel/CDDP or S1/CDDP followed by surgery for locally advanced gastric cancer, a randomized phase II trial (COMPASS).
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms COMPASS
- 11 Oct 2016 Results of pharmacogenomic substudy (n=80) presented at the 41st European Society for Medical Oncology Congress.
- 28 May 2016 Primary endpoint has not been met. (3-year overall survival (OS)), as per results published in the European Journal of Cancer.
- 28 May 2016 Results published in the European Journal of Cancer
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History